Sunstone Life Science Ventures

We help turn new science into new products, improving outcome for patients And we help create value for innovators, investors and health care systems around the world

Sunstone Life Science Ventures invests in early-stage life science companies developing novel therapeutics for humans

Our portfolio is managed through a series of funds Fund IV, focusing solely on therapeutics, is actively pursuing new investment opportunities

An overview of the companies in our portfolio – currently active, completed M&As and completed IPOs

Newest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history

Find our visiting address, contact info and some guidance and a contact form for submitting projects for evaluation

New science becomes new products

Since the inception of Sunstone in 2007, we have contributed in bringing several new drugs into the market and have supported a large number of clinical trials:

Clinical phase 1 studies

Clinical phase 2 studies

Clinical phase 3 studies

Sunstone Life Science Ventures is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing